FDA Approved: BEYFORTUS — Supplemental Application (Sanofi Vaccines US Inc.)

View source ↗

Summary

FDA approved a supplemental application for Beyfortus (nirsevimab) from Sanofi Vaccines US Inc., related to an update/expansion of the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• BEYFORTUS (Nirsevimab)

Snippet

SUPPL AP for BEYFORTUS (NIRSEVIMAB)